Track Sonoma Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Sonoma Pharmaceuticals, Inc. SNOA · Stock Open Sonoma Pharmaceuticals, Inc. in new tab

1.09 USD
EPS
-1.95
P/B
0.58
ROE
-81.18
Beta
1.29
Loading chart...
Key Metrics
Earnings dateJuly 15, 2026
EPS-1.95
Book Value1.98
Price to Book0.58
Debt/Equity19.09
% Insiders0.573%
Growth
Revenue Growth0.22%
Estimates
Forward P/E-2.07
Forward EPS-0.56

DCF Valuation

Tweak assumptions to recompute fair value for Sonoma Pharmaceuticals, Inc. (SNOA)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Sonoma Pharmaceuticals, Inc. Logo Sonoma Pharmaceuticals, Inc. Analysis (SNOA)

United States Health Care Official Website Stock

Is Sonoma Pharmaceuticals, Inc. a good investment? Sonoma Pharmaceuticals, Inc. (SNOA) is currently trading at 1.09 USD.

Earnings Schedule: Sonoma Pharmaceuticals, Inc. is expected to release its next earnings report on July 15, 2026. The market consensus estimate for Forward EPS is -0.56.

Investor FAQ

Does Sonoma Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Sonoma Pharmaceuticals, Inc.?

Sonoma Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be July 15, 2026. The company currently has a trailing EPS of -1.95.

Company Profile

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Exchange Ticker
NMS (United States) SNOA
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 1, 2013 0.140000
June 27, 2016 0.200000
June 20, 2019 0.110000
Aug. 30, 2024 0.050000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion